GlassScriptPhysician profile
Robert Craven Snyder
NPI 1447369590
$15,057.64
in general payments reported to CMS, 2019-2025
58 companies · $2,131 in 2025
The $2,131 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,825 · 2020: $1,824 · 2021: $2,456 · 2022: $2,380 · 2023: $1,971 · 2024: $2,471 · 2025: $2,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,572.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,328.61 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $1,795.51 | 2019-2025 | |
| Lilly USA, LLC | $1,306.34 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Glaxosmithkline, LLC. | $1,223.13 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $906.67 | 2019-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $715.66 | 2022-2025 | Freestyle Libre, Freestyle Libre 2, Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $634.43 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $520.57 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Allergan, INC. | $428.60 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $421.44 | 2019-2022 | |
| Dexcom, INC. | $406.02 | 2021-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $383.63 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $377.75 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $316.66 | 2019-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $228.61 | 2019-2024 | Eliquis |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.